Company intelligence / Profile preview
Heqet Therapeutics
Torino, Piedmont, Italy
- Ownership
- Private
- Development stage
- Other
01
Overview
Heqet Therapeutics has not yet entered clinical trials; its RNA-based therapies for cardiac regeneration are currently in pre-clinical development. Their goal is to create first-in-class therapies for heart failure following myocardial infarction, with recent financing secured to support pre-clinical work and advance towards clinical trials
- Therapeutic areas
- Cardiovascular
- Modalities
- Non-coding RNA therapyRNA therapyLipid nanoparticle delivery therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Ethris (for SNaP LNP platform and RNA delivery technology)
Beyond the preview
Go deeper on Heqet Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heqet Therapeutics.